These findings suggest that PSMA PET/CT is not only pivotal in the initial diagnosis and staging but also plays a significant role in the ongoing assessment and monitoring of prostate cancer, facilitating timely and informed therapeutic interventions. The gene discussed is FOLH1; the disease is prostate carcinoma.